Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis

William R. Kirkpatrick, Sofia Perea, Brent J. Coco, Thomas F. Patterson

Research output: Contribution to journalArticle

33 Scopus citations

Abstract

Ravuconazole (BMS-207147, ER-30346), an oral triazole, was evaluated in an immunosuppressed temporarily neutropenic guinea pig model of invasive aspergillosis. In this model, guinea pigs were immunosuppressed with triamcinolone 20 mg/kg sc od beginning 4 days before challenge and made neutropenic with cyclophosphamide 300 mg/kg ip 1 day before challenge. Treatments of ravuconazole 5, 10 and 25 mg/kg po od were compared with itraconazole 2.5 and 5.0 mg/kg po bd and amphotericin B 1.25 mg/kg ip od. Treatment began 24 h after lethal intravenous challenge with Aspergillus fumigatus and continued for 5 days. Mortality occurred in eight of eight untreated control animals versus none of eight treated with ravuconazole 5 or 10 mg/kg/day or itraconazole 10 mg/kg/day. Mortality occurred in one of eight animals treated with ravuconazole 25 mg/kg/day, one of eight with amphotericin B and two of eight treated with itraconazole 5 mg/kg/day. Compared with controls, each of the antifungals examined significantly reduced the tissue burden in liver and brain, although only the highest doses of the azole drugs and amphotericin B significantly reduced tissue burden in the kidney. All three doses of ravuconazole improved survival and also reduced the tissue burden of Aspergillus. In this model of invasive aspergillosis, ravuconazole showed significant activity and may be a useful compound in human disease.

Original languageEnglish (US)
Pages (from-to)353-357
Number of pages5
JournalJournal of Antimicrobial Chemotherapy
Volume49
Issue number2
DOIs
StatePublished - 2002

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis'. Together they form a unique fingerprint.

  • Cite this